Lineage Cell Therapeutics, Inc.

1.01 USD
+0.01 (+1.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Lineage Cell Therapeutics, Inc. stock is down -6.48% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 31 December’s closed higher than November.

About Lineage Cell Therapeutics, Inc.

OpRegen, a retinal pigment epithelium cell replacement therapy, is in Phase I/IIa clinical trial for the treatment of dry age-related macular degeneration. OPC1, an oligodendrocyte progenitor cell therapy, and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, are in clinical trials to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product.